Specialized Disclosure Report (sd)
May 27 2021 - 4:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
Harvard Bioscience, Inc.
(Exact name of the registrant as specified in its charter)
DELAWARE
|
001-33957
|
04-3306140
|
(State or Other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
84 October Hill Road, Holliston, MA
|
01746
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Michael A. Rossi
|
(508) 893-8999
|
(Name and telephone number, including area code, of the person to contact in connection with this report.)
|
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and
provide the period to which the information in this form applies:
ý Rule
13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2020.
Section 1 - Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
Harvard Bioscience, Inc. (“Harvard Bioscience” or “the Company”) has
evaluated its current product lines and has determined in good faith that during 2020 it manufactured or contracted to manufacture products
as to which columbite-tantalite (coltan), cassiterite, gold, wolframite and their derivatives, which are limited to tantalum, tin, and
tungsten (herein referred to as “Conflict Minerals”) are necessary to the functionality or production of such products (herein
referred to as “Covered Products”). Based on such determination, Harvard Bioscience conducted a reasonable country of origin
inquiry, or RCOI, that was reasonably designed to determine whether any of the Conflict Minerals in the Covered Products originated in
the Democratic Republic of the Congo or an adjoining country (the Republic of the Congo, the Central African Republic, South Sudan, Uganda,
Rwanda, Burundi, Tanzania, Zambia or Angola) or were from recycled or scrap sources.
Following the RCOI, Harvard Bioscience exercised due diligence on the source and chain of custody
of its applicable products. Information on the RCOI, steps we have taken to exercise due diligence on the source and chain of custody
of any Conflict Minerals in the Covered Products and the results of this due diligence, are disclosed in the Conflict Minerals Report
filed as Exhibit 1.01 to this Form SD.
Conflict Minerals Disclosure
A copy of Harvard Bioscience’s Conflict Minerals Report is filed as Exhibit 1.01 hereto
and is publicly available at: http://investor.harvardbioscience.com/corporate-governance.cfm. The content of any website referred to in
this Form SD is included for general information only and is not incorporated by reference in this Form SD.
Item 1.02 Exhibit
Harvard Bioscience, Inc. has filed its Conflict Minerals Report as Exhibit 1.01 to this Form
SD.
Section 2 - Exhibits
Item 2.01 Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the duly authorized undersigned.
Harvard Bioscience, Inc.
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
/s/ Michael A. Rossi
|
|
May 27, 2021
|
|
By: Michael A. Rossi, Chief Financial Officer
|
|
|
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024